ScholarIQanswers from OpenAlex

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma

PaperCitations, authors & open-access status

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma have?

ScholarIQcitation count

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma has 63 citations in the OpenAlex counts ScholarIQ stores.

When was High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma published?

ScholarIQyear

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma has 2014 year in the ScholarIQ index.

What is the open-access status of High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma?

ScholarIQoa status

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma has diamond oa status in the ScholarIQ index.

What is the DOI of High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma?

ScholarIQdoi

The DOI for High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma is on the source record.

What is the PMID of High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma?

ScholarIQpmid

The PMID for High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma is on the source record.

What is the OpenAlex record for High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma?

ScholarIQopenalex

The OpenAlex for High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial